Michael Soileau, Rajeev Kumar, Ashwini Parab, Triza Brion, Kailee White, Connie H Yan, Megha B Shah, Pavnit Kukreja, Maurizio F Facheris, Anand Shewale, Jason Aldred
{"title":"Patients' experience with and perspectives on long-term use of continuous subcutaneous infusion of foslevodopa/foscarbidopa in Parkinson's disease.","authors":"Michael Soileau, Rajeev Kumar, Ashwini Parab, Triza Brion, Kailee White, Connie H Yan, Megha B Shah, Pavnit Kukreja, Maurizio F Facheris, Anand Shewale, Jason Aldred","doi":"10.1007/s00415-025-13123-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to assess ease of use, convenience, self-efficacy, and satisfaction with long-term use of foslevodopa/foscarbidopa (LDp/CDp), a 24-h continuous subcutaneous infusion therapy delivered via an external portable pump for managing motor fluctuations in people with Parkinson's disease (PwP).</p><p><strong>Methods: </strong>PwP using LDp/CDp for ≥ 6 months and enrolled in an open-label study participated in semi-structured interviews, which were qualitatively analyzed using a content and thematic approach.</p><p><strong>Results: </strong>Nineteen adults, with an average (standard deviation) age of 63.6 (10.8) years, disease duration of 9.2 (3.4) years, and duration of LDp/CDp use of 15.4 (3.4) months, were interviewed. Most found LDp/CDp to be user-friendly (89.5%) and reliable (100%), and developed strategies to integrate the pump into their daily lives. The pump was commonly worn crossbody or around the waist, with minimal impact on sleep, though participants emphasized being mindful of the infusion set tubing to prevent tangling. Participants established routines using reminders, alarms, or schedules, and 84.2% prepared the pump in ≤ 20 min. Most (81.3%) were confident using LDp/CDp independently and 92.3% were satisfied with LDp/CDp, citing improved, consistent symptom control that allowed more freedom to participate in daily and social activities. Participants suggested improvements for the pump, including making it smaller and lighter.</p><p><strong>Conclusion: </strong>PwP expressed high satisfaction and willingness to continue using LDp/CDp. PwP and their care partners developed innovative strategies to integrate the pump into daily routines, and the perceived symptom improvement drove successful persistence on this well-tolerated treatment.</p><p><strong>Trial registration: </strong>NCT04750226; started February 18, 2021.</p>","PeriodicalId":16558,"journal":{"name":"Journal of Neurology","volume":"272 6","pages":"416"},"PeriodicalIF":4.8000,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12098408/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00415-025-13123-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Objectives: We aimed to assess ease of use, convenience, self-efficacy, and satisfaction with long-term use of foslevodopa/foscarbidopa (LDp/CDp), a 24-h continuous subcutaneous infusion therapy delivered via an external portable pump for managing motor fluctuations in people with Parkinson's disease (PwP).
Methods: PwP using LDp/CDp for ≥ 6 months and enrolled in an open-label study participated in semi-structured interviews, which were qualitatively analyzed using a content and thematic approach.
Results: Nineteen adults, with an average (standard deviation) age of 63.6 (10.8) years, disease duration of 9.2 (3.4) years, and duration of LDp/CDp use of 15.4 (3.4) months, were interviewed. Most found LDp/CDp to be user-friendly (89.5%) and reliable (100%), and developed strategies to integrate the pump into their daily lives. The pump was commonly worn crossbody or around the waist, with minimal impact on sleep, though participants emphasized being mindful of the infusion set tubing to prevent tangling. Participants established routines using reminders, alarms, or schedules, and 84.2% prepared the pump in ≤ 20 min. Most (81.3%) were confident using LDp/CDp independently and 92.3% were satisfied with LDp/CDp, citing improved, consistent symptom control that allowed more freedom to participate in daily and social activities. Participants suggested improvements for the pump, including making it smaller and lighter.
Conclusion: PwP expressed high satisfaction and willingness to continue using LDp/CDp. PwP and their care partners developed innovative strategies to integrate the pump into daily routines, and the perceived symptom improvement drove successful persistence on this well-tolerated treatment.
Trial registration: NCT04750226; started February 18, 2021.
期刊介绍：
The Journal of Neurology is an international peer-reviewed journal which provides a source for publishing original communications and reviews on clinical neurology covering the whole field.
In addition, Letters to the Editors serve as a forum for clinical cases and the exchange of ideas which highlight important new findings. A section on Neurological progress serves to summarise the major findings in certain fields of neurology. Commentaries on new developments in clinical neuroscience, which may be commissioned or submitted, are published as editorials.
Every neurologist interested in the current diagnosis and treatment of neurological disorders needs access to the information contained in this valuable journal.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
